LISTING OF CLAIMS: This listing of claims replaces all prior versions and listings of claims in the instant patent application.

1. (previously presented) A compound 12 to 50 nucleobases in length targeted to a region comprising nucleotide 901 to 950 of the nucleic acid molecule encoding diacylglycerol acyltransferase 2 in SEQ ID NO: 4, wherein said compound is at least 80% complementary to said nucleic acid molecule encoding diacylglycerol acyltransferase 2, and wherein said compound comprises at least an 8 nucleobase portion of SEQ ID NO: 35, 36, 37 or 38.

2. (canceled)

3. (previously presented) The compound of claim 1 comprising 15 to 30 nucleobases in length.

4. (original) The compound of claim 1 comprising an oligonucleotide.

5. (original) The compound of claim 4 comprising an antisene oligonucleotide.

6. (original) The compound of claim 4 comprising a DNA oligonucleotide.

7. (original) The compound of claim 4 comprising a RNA oligonucleotide.

8. (original) The compound of claim 4 comprising a chimeric oligonucleotide.

9. (original) The compound of claim 4 wherein at least a portion of said compound hybridizes with RNA to form an oligonucleotide-RNA duplex.

10. (canceled).

11. (original) The compound of claim 1 having at least 90% complementarity with said nucleic acid molecule encoding diacylglycerol acyltransferase 2.

12. (original) The compound of claim 1 having at least 95% complementarity with said nucleic acid molecule encoding diacylglycerol acyltransferse 2.

13. (previously presented) The compound of claim 1 having 100% complementarity with said nucleic acid molecule encoding diacylglycerol acyltranferase 2.

14. (original) The compound of claim 1 havig at least one modfied internucleoside linkage, sugar moiety, or nucleobase.

15. (original) The compound of claim 1 having at least one 2'-O-methoxyethyl sugar moiety.

16. (original) The compound of claim 1 having at least one phosphorothioate internucleoside linkage.

17. (original) The compound of claim 1 having at least one 5-methylcytosine.

18. (previously presented) A method of inhibiting the expression of diacylglycerol acyltransferase 2 in a cell or tissue comprising contacting said cell or tissue with the compound of claim 1 so that expression of diacylglycerol acyltransferase 2 is inhbited.

19. - 21. (canceled)

22. (original) A kit or assay device comprising the compound of claim 1.

23. (previously presented) A method of ameliorating or lessening the severity of a condition in an animal comprising contacting said animal with an effective amount of the compound of claim 1 so that expression of diacylglycerol acyltransferase 2 is inhibited and measurement of one or more physical indicia of said condition indicates a lessening of the severity of said condition.

24. (previously presented) The method of claim 23 wherein the condition is a cardiovascular disorder.

25. (previously presented) The method of claim 23 wherein the condition is obesity.

26. (previously presented) The method of claim 25 wherein the obesity is diet-induced.

27. (previously presented) The method of claim 25 wherein physical indicia of obesity is increased fat.

28. (previously presented) The method of claim 23 wherein the condition is diabetes.

29. (previously presented) The method of claim 23 wherein the condition is cholesterolemia.

30. (previously presented) The method of claim 23 wherein the condition is liver steatosis.

31. (previously presented) The method of claim 23 wherein the animal is obese.

32. (previously presented) The method of claim 23 wherein the animal is a mammal.

33. (currently amended) ~~A~~ The method of claim 23 wherein said measurement comprises ~~lowering~~ serum free fatty acids ~~in an animal comprising contacting said animal with an effective amount of the compound of claim 4~~.

34. (currently amended) ~~A~~ The method of claim 23 wherein said measurement comprises ~~lowering~~ serum triglycerides ~~in an animal comprising contacting said animal with an effective amount of the compound of claim 4~~.

35. (currently amended) ~~A~~ The method of claim 23 wherein said measurement comprises ~~lowering~~ HDL cholesterol ~~in an animal comprising contacting said animal with an effective amount of the compound of claim 4~~.

36. (currently amended) ~~A~~ The method of claim 23 wherein said measurement comprises ~~lowering~~ total serum cholesterol ~~in an animal comprising contacting said animal with an effective amount of the compound of claim 4~~.

37. (currently amended) ~~A~~ The method of claim 23 wherein said measurement comprises ~~lowering~~ plasma insulin ~~in an animal comprising contacting said animal with an effective amount of the compound of claim 4~~.

38. (currently amended) A The method of claim 23 wherein said measurement comprises lowering hepatic triglycerides ~~in an animal comprising contacting said animal with an effective amount of the compound of claim 4~~.

39. (currently amended) The method of claim 37 wherein said plasma insulin levels are lowered at two weeks after ~~said~~ contacting.

40. (currently amended) The method of claim 37 wherein said plasma insulin levels are lowered at four weeks after ~~said~~ contacting.

41. - 43. (canceled)

44. (original) The compound of claim 1 , wherein said compound comprises an antisense nucleic acid molecule that is specifically hybridizable with a coding region of the diacylglycerol acyltransferase 2 (SEQ ID NO: 4).

45. - 48. (canceled)

49. (previously presented) A method of inhibiting the expression of diacylglycerol acyltranferase 2 in a cell or tissue of an animal comprising contacting said cell or tissue with the compound of claim 1 so that expression of diacylglycerol acyltransferase 2 is inhibited.

50. (previously presented) The method of claim 49 wherein said tissue is white adipose tissue.

51. (previously presented) The method of claim 49 wherein the tissue is brown adipose tissue.

52. (previously presented) A method of modulating fatty acid synthesis in an animal comprising contacting said animal with the compound of claim 4.

53. (previously presented) A method of modulating lipogenesis in an animal comprising contacting said animal with the compound of claim 4.

54. (previously presented) A method of modulating gluconeogenesis in an animal comprising contacting said animal with the compound of claim 4.

55. (previously presented) A method of reducing the liver weight of an animal comprising contacting said animal with the compound of claim 4.

56. (previously presented) The method of claim 55 wherein the animal is obese.

57. (previously presented) The method of claim 55 wherein the animal is diabetic.

58. (previously presented) The compound of claim 1, wherein said compound is 20 nucleobases in length.

59. (previously presented) The compound of claim 13 having at least one modified intenucleoside linkage, sugar moiety, or nucleobase.

60. (previously presented) A compound 20 nucleobases in length targeted to a nucleic acid molecule encoding diacylglycerol acyltransferase 2 (SEQ ID NO: 4), wherein said compound has the nucleobase sequence of SEQ ID NO: 35.